valproic acid has been researched along with Aging in 60 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Aging: The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This randomized control study was conducted to compare the efficacy of sodium valproate (SVP) and levetiracetam (LEV) following initial intravenous lorazepam in elderly patients (age: >60years) with generalized convulsive status epilepticus (GCSE) and to identify predictors of poor seizure control." | 9.30 | Comparing the efficacy of sodium valproate and levetiracetam following initial lorazepam in elderly patients with generalized convulsive status epilepticus (GCSE): A prospective randomized controlled pilot study. ( Bharath, RD; Bindu, PS; Mundlamuri, RC; Nagappa, M; Nene, D; Prathyusha, PV; Raghavendra, K; Saini, J; Satishchandra, P; Sinha, S; Taly, AB; Thennarasu, K, 2019) |
| "Immature rats are more susceptible to clonic seizures induced by aminooxyacetic acid (AOAA) than mature and senile rats." | 7.68 | Age dependency of the susceptibility of rats to aminooxyacetic acid seizures. ( Cavalheiro, EA; Dziki, M; Kleinrok, Z; Parada, J; Turski, W, 1992) |
| "Valproic acid is a branched-chained fatty acid, structurally unrelated to any other antiepileptic drug." | 6.39 | Valproic acid. A reappraisal of its pharmacological properties and clinical efficacy in epilepsy. ( Davis, R; McTavish, D; Peters, DH, 1994) |
| "The incidence of seizures, their expression pattern and their latencies were registered and the severity was expressed by means of a five-point scale." | 5.39 | Derivatives of valproic acid are active against pentetrazol-induced seizures in immature rats. ( Bialer, M; Hen, N; Kubová, H; Mareš, P; Yagen, B, 2013) |
| "Valproic acid (VPA) is a widely used anticonvulsant that is also approved for mood disorders, bipolar depression, and migraine." | 5.35 | Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. ( Argikar, UA; Remmel, RP, 2009) |
| "This randomized control study was conducted to compare the efficacy of sodium valproate (SVP) and levetiracetam (LEV) following initial intravenous lorazepam in elderly patients (age: >60years) with generalized convulsive status epilepticus (GCSE) and to identify predictors of poor seizure control." | 5.30 | Comparing the efficacy of sodium valproate and levetiracetam following initial lorazepam in elderly patients with generalized convulsive status epilepticus (GCSE): A prospective randomized controlled pilot study. ( Bharath, RD; Bindu, PS; Mundlamuri, RC; Nagappa, M; Nene, D; Prathyusha, PV; Raghavendra, K; Saini, J; Satishchandra, P; Sinha, S; Taly, AB; Thennarasu, K, 2019) |
| "Valproic acid, a new type of antiepileptic drug, has developed into one of the drugs of first choice in all types of epilepsy with the exception of infantile spasms and partial seizures." | 4.76 | Therapeutic monitoring of valproic acid. ( Schobben, F; van der Kleijn, E; Vree, TB, 1980) |
| " Recent studies suggest that aging may be associated with epigenetic changes and that valproic acid (VPA), a histone deacetylase inhibitor, may reverse such changes." | 3.80 | HDAC inhibitors restore the capacity of aged mice to respond to haloperidol through modulation of histone acetylation. ( Csernansky, JG; Dong, H; Fang, D; Gallardo, C; Gerst, N; Keegan, J; Matsumoto, M; Montalvo-Ortiz, JL; Tetsuka, K; Tucker, C, 2014) |
| "To evaluate the influence of aging on the pharmacokinetics of valproic acid (VPA) at steady-state and on the susceptibility of VPA metabolism to enzyme induction by antiepileptic comedication." | 3.73 | The influence of old age and enzyme inducing comedication on the pharmacokinetics of valproic acid at steady-state: A case-matched evaluation based on therapeutic drug monitoring data. ( Battino, D; Croci, D; Fattore, C; Mamoli, D; Messina, S; Perucca, E, 2006) |
| " The multiple peak approach has been used to evaluate the effect of age, total body weight, dose, gender and comedication (carbamazepine-induced change) on population estimates of valproic acid relative clearance." | 3.69 | Detection of carbamazepine-induced changes in valproic acid relative clearance in man by simple pharmacokinetic screening. ( Aoyama, T; Higuchi, S; Honda, T; Ohdo, S; Yukawa, E, 1997) |
| "Immature rats are more susceptible to clonic seizures induced by aminooxyacetic acid (AOAA) than mature and senile rats." | 3.68 | Age dependency of the susceptibility of rats to aminooxyacetic acid seizures. ( Cavalheiro, EA; Dziki, M; Kleinrok, Z; Parada, J; Turski, W, 1992) |
| "Since its initial 1957 description, juvenile myoclonic epilepsy (JME) has been recognized as a common epileptic syndrome worldwide." | 2.55 | Juvenile myoclonic epilepsy: Challenges on its 60th anniversary. ( Yacubian, EM, 2017) |
| "Valproic acid is a branched-chained fatty acid, structurally unrelated to any other antiepileptic drug." | 2.39 | Valproic acid. A reappraisal of its pharmacological properties and clinical efficacy in epilepsy. ( Davis, R; McTavish, D; Peters, DH, 1994) |
| "Anticonvulsant therapy was among the first areas to benefit from clinical pharmacokinetic studies." | 2.35 | Clinical pharmacokinetics of anticonvulsants. ( Dam, M; Hvidberg, EF, 1976) |
| "These results suggest that epigenetic changes at the striatal Drd2 promoter drive age-related increases in antipsychotic side effect susceptibility, and HDAC inhibitors may be an effective adjunct treatment strategy to reduce side effects in aged populations." | 1.46 | Histone deacetylase inhibitors reverse age-related increases in side effects of haloperidol in mice. ( Csernansky, JG; Dong, H; Fang, D; Fisher, DW; Montalvo-Ortiz, JL; Rodríguez, G, 2017) |
| "Sleep deprivation increased seizure susceptibility in adult sesB(9ed4)/+ and sei(ts1) mutant flies." | 1.42 | A new model to study sleep deprivation-induced seizure. ( Leahy, A; Lucey, BP; Rosas, R; Shaw, PJ, 2015) |
| "The incidence of seizures, their expression pattern and their latencies were registered and the severity was expressed by means of a five-point scale." | 1.39 | Derivatives of valproic acid are active against pentetrazol-induced seizures in immature rats. ( Bialer, M; Hen, N; Kubová, H; Mareš, P; Yagen, B, 2013) |
| "Fourteen patients developed seizures during that period and 25 did not." | 1.37 | Risk factors for late-onset seizures related to cerebral contusions in adults with a moderate traumatic brain injury. ( De Reuck, J, 2011) |
| "Autism is characterized by behavioral impairments in three main domains: social interaction; language, communication and imaginative play; and range of interests and activities." | 1.37 | Animal model of autism induced by prenatal exposure to valproate: behavioral changes and liver parameters. ( Bambini-Junior, V; Behr, GA; Gottfried, C; Moreira, JC; Riesgo, R; Rodrigues, L, 2011) |
| "Epilepsy was confirmed in 58 cases." | 1.37 | [Epilepsy in elderly]. ( Kotov, AS; Rudakova, IG, 2011) |
| "Epilepsy was diagnosed in 37% (375/1014) of the study participants." | 1.36 | Correlation between EEG abnormalities and symptoms of autism spectrum disorder (ASD). ( Yasuhara, A, 2010) |
| "Rapid cycling with co-occurring substance use is not only associated with poor response to mood stabilizers, but is also a harbinger of serious medical problems." | 1.35 | Medical and substance use comorbidity in bipolar disorder. ( Bilali, S; Calabrese, JR; Caldes, E; Chan, PK; Conroy, C; Feldman, K; Findling, RL; Ganocy, SJ; Gao, K; Kemp, DE, 2009) |
| " Future prospective studies are necessary to clarify whether the prescribed dosage should be different in young and older patients." | 1.34 | Age and gender effects on olanzapine and risperidone plasma concentrations in children and adolescents. ( Aichhorn, W; Hinterhuber, H; Kemmler, G; Marksteiner, J; Stuppaeck, C; Walch, T; Zernig, G, 2007) |
| "Valproic acid (VPA) has a narrow therapeutic range (50-100mg/l) and exhibits nonlinear protein binding." | 1.32 | Oral/intravenous maintenance dosing of valproate following intravenous loading: a simulation. ( Cloyd, JC; Collins, SD; Dutta, S; Granneman, GR, 2003) |
| " Chronic administration of pentyl-4-yn-VPA (16." | 1.31 | Pentyl-4-yn-valproic acid enhances both spatial and avoidance learning, and attenuates age-related NCAM-mediated neuroplastic decline within the rat medial temporal lobe. ( Foley, AG; Fox, GB; Gallagher, HC; Griffin, AM; Murphy, KJ; Nau, H; O'Connell, A; Regan, CM, 2001) |
| "05) variability in pharmacokinetic values than patients receiving monotherapy." | 1.29 | Valproic acid pharmacokinetics in children. IV. Effects of age and antiepileptic drugs on protein binding and intrinsic clearance. ( Cloyd, JC; Fischer, JH; Kraus, DM; Kriel, RL, 1993) |
| "Free plasma level/dose ratio of valproic acid (L/D-F) can be more effective than total plasma level/dose ratio (L/D-T) in adjusting dosage regimens." | 1.28 | Total and free valproic acid: plasma level/dose ratio in monotherapy. ( Abadín, JA; Durán, JA; Sánchez, A; Serrano, JS, 1991) |
| " These findings should therefore be considered when defining dosage regimens or interpreting serum drug concentrations." | 1.28 | Analysis of the factors influencing anti-epileptic drug concentrations--valproic acid. ( Aoyama, T; Higuchi, S; Hirata, K; Ieiri, I; Yamada, H, 1990) |
| " These findings suggest that the pharmacokinetic alterations of VPA in old age are complex and include at least two separate mechanisms: a decrease in plasma protein binding and a reduction of drug metabolizing capacity resulting in decreased clearance of free drug by the liver." | 1.27 | Pharmacokinetics of valproic acid in the elderly. ( Crema, F; Frigo, GM; Gatti, G; Grimaldi, R; Perucca, E; Pirracchio, S, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (11.67) | 18.7374 |
| 1990's | 17 (28.33) | 18.2507 |
| 2000's | 15 (25.00) | 29.6817 |
| 2010's | 20 (33.33) | 24.3611 |
| 2020's | 1 (1.67) | 2.80 |
| Authors | Studies |
|---|---|
| Pei, W | 1 |
| Fu, L | 1 |
| Li, SQ | 1 |
| Yu, Y | 1 |
| Montalvo-Ortiz, JL | 2 |
| Fisher, DW | 1 |
| Rodríguez, G | 1 |
| Fang, D | 2 |
| Csernansky, JG | 2 |
| Dong, H | 2 |
| Fueta, Y | 1 |
| Sekino, Y | 1 |
| Yoshida, S | 1 |
| Kanda, Y | 1 |
| Ueno, S | 1 |
| Nene, D | 1 |
| Mundlamuri, RC | 1 |
| Satishchandra, P | 1 |
| Prathyusha, PV | 1 |
| Nagappa, M | 1 |
| Bindu, PS | 1 |
| Raghavendra, K | 1 |
| Saini, J | 1 |
| Bharath, RD | 1 |
| Thennarasu, K | 1 |
| Taly, AB | 1 |
| Sinha, S | 1 |
| Ohira, K | 1 |
| Kobayashi, K | 1 |
| Toyama, K | 1 |
| Nakamura, HK | 1 |
| Shoji, H | 1 |
| Takao, K | 1 |
| Takeuchi, R | 1 |
| Yamaguchi, S | 1 |
| Kataoka, M | 1 |
| Otsuka, S | 1 |
| Takahashi, M | 1 |
| Miyakawa, T | 1 |
| Mareš, P | 3 |
| Kubová, H | 1 |
| Hen, N | 1 |
| Yagen, B | 1 |
| Bialer, M | 1 |
| Keegan, J | 1 |
| Gallardo, C | 1 |
| Gerst, N | 1 |
| Tetsuka, K | 1 |
| Tucker, C | 1 |
| Matsumoto, M | 1 |
| Noh, H | 1 |
| Seo, H | 1 |
| Sosa-Díaz, N | 1 |
| Bringas, ME | 1 |
| Atzori, M | 1 |
| Flores, G | 1 |
| Cusmano, DM | 1 |
| Mong, JA | 1 |
| Lucey, BP | 1 |
| Leahy, A | 1 |
| Rosas, R | 1 |
| Shaw, PJ | 1 |
| Robitsek, J | 1 |
| Ratner, MH | 1 |
| Stewart, T | 1 |
| Eichenbaum, H | 1 |
| Farb, DH | 1 |
| Zimmermann, FF | 1 |
| Gaspary, KV | 1 |
| Siebel, AM | 1 |
| Leite, CE | 1 |
| Kist, LW | 1 |
| Bogo, MR | 1 |
| Bonan, CD | 1 |
| Bhat, J | 1 |
| Sosna, J | 1 |
| Fritsch, J | 1 |
| Quabius, ES | 1 |
| Schütze, S | 1 |
| Zeissig, S | 1 |
| Ammerpohl, O | 1 |
| Adam, D | 1 |
| Kabelitz, D | 1 |
| Yacubian, EM | 1 |
| Argikar, UA | 1 |
| Remmel, RP | 1 |
| Kemp, DE | 1 |
| Gao, K | 1 |
| Ganocy, SJ | 1 |
| Caldes, E | 1 |
| Feldman, K | 1 |
| Chan, PK | 1 |
| Conroy, C | 1 |
| Bilali, S | 1 |
| Findling, RL | 1 |
| Calabrese, JR | 1 |
| Shen, S | 1 |
| Sandoval, J | 1 |
| Swiss, VA | 1 |
| Li, J | 1 |
| Dupree, J | 1 |
| Franklin, RJ | 1 |
| Casaccia-Bonnefil, P | 1 |
| Spina, E | 1 |
| D'Arrigo, C | 1 |
| Santoro, V | 1 |
| Muscatello, MR | 1 |
| Pandolfo, G | 1 |
| Zoccali, R | 1 |
| Diaz, FJ | 1 |
| de Leon, J | 1 |
| Koh, MT | 1 |
| Haberman, RP | 1 |
| Foti, S | 1 |
| McCown, TJ | 1 |
| Gallagher, M | 1 |
| Yasuhara, A | 1 |
| De Reuck, J | 1 |
| Bambini-Junior, V | 1 |
| Rodrigues, L | 1 |
| Behr, GA | 1 |
| Moreira, JC | 1 |
| Riesgo, R | 1 |
| Gottfried, C | 1 |
| Kotov, AS | 1 |
| Rudakova, IG | 1 |
| Nishigori, H | 2 |
| Kagami, K | 1 |
| Takahashi, A | 1 |
| Tezuka, Y | 1 |
| Sanbe, A | 1 |
| Stephen, LJ | 1 |
| Dutta, S | 1 |
| Cloyd, JC | 2 |
| Granneman, GR | 1 |
| Collins, SD | 1 |
| Jeong, MR | 1 |
| Hashimoto, R | 1 |
| Senatorov, VV | 1 |
| Fujimaki, K | 1 |
| Ren, M | 1 |
| Lee, MS | 1 |
| Chuang, DM | 1 |
| Foley, AG | 2 |
| Gallagher, HC | 2 |
| Murphy, KJ | 2 |
| Regan, CM | 2 |
| Fattore, C | 1 |
| Messina, S | 1 |
| Battino, D | 1 |
| Croci, D | 1 |
| Mamoli, D | 1 |
| Perucca, E | 2 |
| Sproule, B | 1 |
| Nava-Ocampo, AA | 1 |
| Kapur, B | 1 |
| Aichhorn, W | 1 |
| Marksteiner, J | 1 |
| Walch, T | 1 |
| Zernig, G | 1 |
| Hinterhuber, H | 1 |
| Stuppaeck, C | 1 |
| Kemmler, G | 1 |
| Espandiari, P | 1 |
| Zhang, J | 1 |
| Schnackenberg, LK | 1 |
| Miller, TJ | 1 |
| Knapton, A | 1 |
| Herman, EH | 1 |
| Beger, RD | 1 |
| Hanig, JP | 1 |
| Grimaldi, R | 1 |
| Gatti, G | 1 |
| Pirracchio, S | 1 |
| Crema, F | 1 |
| Frigo, GM | 1 |
| Morselli, PL | 1 |
| Franco-Morselli, R | 1 |
| Schobben, F | 1 |
| van der Kleijn, E | 1 |
| Vree, TB | 1 |
| Davis, R | 1 |
| Peters, DH | 1 |
| McTavish, D | 1 |
| Slattum, PW | 1 |
| Cato, AE | 1 |
| Pollack, GM | 2 |
| Brouwer, KL | 2 |
| Cato, A | 1 |
| Scollo-Lavizzari, G | 1 |
| Proeckl, D | 1 |
| Liu, H | 1 |
| Delgado, MR | 1 |
| Stijnen, AM | 1 |
| Hovinga, S | 1 |
| Langemeijer, MW | 1 |
| Hoogerkamp, A | 1 |
| van Bezooijen, CF | 1 |
| Danhof, M | 1 |
| Fischer, JH | 1 |
| Kriel, RL | 1 |
| Kraus, DM | 1 |
| Wikinski, SI | 1 |
| Acosta, GB | 1 |
| Rubio, MC | 1 |
| Coiro, V | 1 |
| Volpi, R | 1 |
| Gramellini, D | 1 |
| Cigarini, C | 1 |
| Necchi Ghiri, S | 1 |
| Capretti, L | 1 |
| Caffarri, G | 1 |
| Chiodera, P | 1 |
| Yukawa, E | 1 |
| Honda, T | 1 |
| Ohdo, S | 1 |
| Higuchi, S | 3 |
| Aoyama, T | 3 |
| Wong, H | 1 |
| Rurak, DW | 1 |
| Kumar, S | 1 |
| Kwan, E | 1 |
| Abbott, FS | 1 |
| Riggs, KW | 1 |
| Reith, DM | 1 |
| Andrews, J | 1 |
| Parker-Scott, S | 1 |
| Eadie, MJ | 1 |
| Fox, GB | 1 |
| O'Connell, A | 1 |
| Griffin, AM | 1 |
| Nau, H | 2 |
| Hvidberg, EF | 1 |
| Dam, M | 1 |
| Stanková, L | 1 |
| Siemes, H | 1 |
| Turski, W | 1 |
| Dziki, M | 1 |
| Parada, J | 1 |
| Kleinrok, Z | 1 |
| Cavalheiro, EA | 1 |
| Abadín, JA | 1 |
| Durán, JA | 1 |
| Sánchez, A | 1 |
| Serrano, JS | 1 |
| Bolaños, JP | 1 |
| Medina, JM | 1 |
| Williamson, DH | 1 |
| Ichikou, N | 1 |
| Ieiri, I | 2 |
| Hirata, K | 2 |
| Yamada, H | 2 |
| Maresová, S | 1 |
| Maresová, D | 1 |
| Monteleone, P | 1 |
| Iovino, M | 1 |
| Orio, F | 1 |
| Steardo, L | 1 |
| Sharma, SK | 1 |
| Selvamurthy, W | 1 |
| Behari, M | 1 |
| Maheshwari, MC | 1 |
| Singh, TP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Bridging Cognitive Aging in Rodents to Man Using fMRI in Amnestic MCI[NCT01044758] | Phase 2 | 96 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| Network-Level Mechanisms for Preclinical Alzheimer's Disease Development[NCT03461861] | Phase 2 | 26 participants (Actual) | Interventional | 2019-04-11 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Mnemonic similarity task which assesses long term memory function. Scale ranges from 0-100 with higher scores indicating better memory performance. (NCT01044758)
Timeframe: 2 weeks
| Intervention | percent correct recalled (Mean) |
|---|---|
| aMCI_62.5 | 38 |
| aMCI_62.5 Placebo | 33 |
| aMCI_125 | 33 |
| aMCI_125 Placebo | 28 |
| aMCI_250 | 34 |
| aMCI_250 Placebo | 31 |
| Age Matched Control | 44 |
Measurement of average brain activity in the dentate gyrus / CA3 subregion of the hippocampus measured with BOLD functional MRI in patients with mild cognitive impairment on placebo and on drug compared to average brain activity in this brain area in control subjects. (NCT01044758)
Timeframe: 2 weeks
| Intervention | mean beta coefficient (Mean) |
|---|---|
| aMCI_62.5 | -0.1203 |
| aMCI_62.5 Placebo | 0.4353 |
| aMCI_125 | -0.2238 |
| aMCI_125 Placebo | 0.8814 |
| aMCI_250 | 0.3928 |
| aMCI_250 Placebo | 0.4825 |
| Age Matched Control | -.02507 |
The seed-based functional connectivity strengths of the hippocampus network and the default mode network will be employed to measure the changes between AGB101 and Placebo perturbation. The functional connectivity strengths will be measured with the median of the Pearson cross-correlation coefficients over entire brain regions. (NCT03461861)
Timeframe: 2 weeks after treatment between AGB101 and Placebo
| Intervention | Pearson coefficient (Median) |
|---|---|
| AGB101 220 mg | 0.233 |
| Placebo | 0.318 |
Rey Auditory Verbal Learning Test (AVLT), delayed recall Scaled integer will be employed to measure the episodic memory changes before and after AGB101 treatment. The AVLT score will be recorded as a standard score. The theoretical range: min 50, max 155, the higher the better. The higher the number is, the better the memory. It is an integer number. (NCT03461861)
Timeframe: Placebo vs AGB101 2 weeks after treatment paired t-test
| Intervention | score on a scale (Mean) |
|---|---|
| AGB101 220 mg | 108 |
| Placebo | 105 |
8 reviews available for valproic acid and Aging
| Article | Year |
|---|---|
Juvenile myoclonic epilepsy: Challenges on its 60th anniversary.
Topics: Age of Onset; Aging; Anniversaries and Special Events; Anticonvulsants; Humans; Myoclonic Epilepsy, | 2017 |
Drug treatment of epilepsy in elderly people: focus on valproic Acid.
Topics: Aged; Aging; Anticonvulsants; Clinical Trials as Topic; Drug Interactions; Epilepsy; Humans; Treatme | 2003 |
Clinical pharmacokinetics of antiepileptic drugs in adults.
Topics: Adult; Aging; Anticonvulsants; Carbamazepine; Clonazepam; Diazepam; Disease; Ethosuximide; Female; H | 1980 |
Therapeutic monitoring of valproic acid.
Topics: Aging; Animals; Autoradiography; Drug Evaluation; Drug Interactions; Epilepsy; Half-Life; Humans; Ki | 1980 |
Valproic acid. A reappraisal of its pharmacological properties and clinical efficacy in epilepsy.
Topics: Adult; Aged; Aging; Animals; Anticonvulsants; Child; Clinical Trials as Topic; Drug Interactions; El | 1994 |
[Sodium valproate--still a current antiepileptic agent?].
Topics: Aging; Drug Interactions; Electroencephalography; Female; gamma-Aminobutyric Acid; Humans; Milk, Hum | 1994 |
Clinical pharmacokinetics of anticonvulsants.
Topics: Administration, Oral; Adult; Aged; Aging; Animals; Anticonvulsants; Carbamazepine; Child; Clonazepam | 1976 |
Differentiation between valproate-induced anticonvulsant effect, teratogenicity and hepatotoxicity. Aspects of species variation, pharmacokinetics, metabolism and implications of structural specificity for the development of alternative antiepileptic agen
Topics: Abnormalities, Drug-Induced; Aging; Animals; Anticonvulsants; Humans; Liver; Structure-Activity Rela | 1992 |
5 trials available for valproic acid and Aging
| Article | Year |
|---|---|
Comparing the efficacy of sodium valproate and levetiracetam following initial lorazepam in elderly patients with generalized convulsive status epilepticus (GCSE): A prospective randomized controlled pilot study.
Topics: Aged; Aged, 80 and over; Aging; Anticonvulsants; Dose-Response Relationship, Drug; Electroencephalog | 2019 |
Measuring unbound versus total valproate concentrations for therapeutic drug monitoring.
Topics: Adolescent; Aged; Aged, 80 and over; Aging; Child; Drug Monitoring; Female; Humans; Male; Middle Age | 2006 |
Altered neuroendocrine control of GH secretion in normal women of advanced reproductive age.
Topics: Adult; Aging; Dopamine Agonists; Female; GABA Agonists; Growth Hormone-Releasing Hormone; Human Grow | 1997 |
Urinary excretion of valproate metabolites in children and adolescents.
Topics: Adolescent; Aging; Anticonvulsants; Biotransformation; Child; Child, Preschool; Chromatography, Gas; | 2000 |
Impaired growth hormone response to sodium valproate in normal aging.
Topics: Adult; Aged; Aged, 80 and over; Aging; gamma-Aminobutyric Acid; Growth Hormone; Humans; Hypothalamo- | 1987 |
47 other studies available for valproic acid and Aging
| Article | Year |
|---|---|
Brain transcriptomics of nonhuman primates: A review.
Topics: Aging; Animals; Brain; Brain Diseases; Disease Models, Animal; Ethanol; Humans; Methamphetamine; Neu | 2021 |
Histone deacetylase inhibitors reverse age-related increases in side effects of haloperidol in mice.
Topics: Acetylation; Aging; Animals; Benzamides; Corpus Striatum; Dopamine Antagonists; Haloperidol; Histone | 2017 |
Prenatal exposure to valproic acid alters the development of excitability in the postnatal rat hippocampus.
Topics: Action Potentials; Aging; Animals; Bicuculline; CA1 Region, Hippocampal; Excitatory Postsynaptic Pot | 2018 |
Synaptosomal-associated protein 25 mutation induces immaturity of the dentate granule cells of adult mice.
Topics: Aging; Animals; Biomarkers; Cytoskeletal Proteins; Dentate Gyrus; Gene Expression Profiling; Gene Kn | 2013 |
Derivatives of valproic acid are active against pentetrazol-induced seizures in immature rats.
Topics: Aging; Allylisopropylacetamide; Amides; Animals; Anticonvulsants; Convulsants; Epilepsy, Generalized | 2013 |
HDAC inhibitors restore the capacity of aged mice to respond to haloperidol through modulation of histone acetylation.
Topics: Acetylation; Aging; Animals; Avoidance Learning; Benzamides; Conditioning, Psychological; Dopamine A | 2014 |
Age-dependent effects of valproic acid in Alzheimer's disease (AD) mice are associated with nerve growth factor (NGF) regulation.
Topics: Aging; Alzheimer Disease; Animals; Blotting, Western; Disease Models, Animal; Enzyme Inhibitors; Hip | 2014 |
Prefrontal cortex, hippocampus, and basolateral amygdala plasticity in a rat model of autism spectrum.
Topics: Aging; Analysis of Variance; Animals; Basolateral Nuclear Complex; Child Development Disorders, Perv | 2014 |
In utero exposure to valproic acid changes sleep in juvenile rats: a model for sleep disturbances in autism.
Topics: Aging; Animals; Arousal; Child Development Disorders, Pervasive; Circadian Rhythm; Disease Models, A | 2014 |
A new model to study sleep deprivation-induced seizure.
Topics: Aging; Animals; Anticonvulsants; Disease Models, Animal; Disease Susceptibility; Drosophila melanoga | 2015 |
Combined administration of levetiracetam and valproic acid attenuates age-related hyperactivity of CA3 place cells, reduces place field area, and increases spatial information content in aged rat hippocampus.
Topics: Action Potentials; Aging; Animals; CA1 Region, Hippocampal; CA3 Region, Hippocampal; Central Nervous | 2015 |
Analysis of Extracellular Nucleotide Metabolism in Adult Zebrafish After Embryological Exposure to Valproic Acid.
Topics: 5'-Nucleotidase; Adenosine Deaminase; Aging; Animals; Brain; Cell Membrane; Embryo, Nonmammalian; Ex | 2017 |
Expression of non-secreted IL-4 is associated with HDAC inhibitor-induced cell death, histone acetylation and c-Jun regulation in human gamma/delta T-cells.
Topics: Aging; Caspase 3; Cell Death; Cells, Cultured; Histone Deacetylase 1; Histone Deacetylase Inhibitors | 2016 |
Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aging; Child; Child, Preschool; Chromatography, High Pre | 2009 |
Medical and substance use comorbidity in bipolar disorder.
Topics: Adult; Affect; Aging; Antimanic Agents; Bipolar Disorder; Comorbidity; Drug Resistance; Drug Therapy | 2009 |
Age-dependent epigenetic control of differentiation inhibitors is critical for remyelination efficiency.
Topics: Aging; Animals; Animals, Newborn; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Cell Diff | 2008 |
Effect of valproate on olanzapine plasma concentrations in patients with bipolar or schizoaffective disorder.
Topics: Adult; Aging; Anticonvulsants; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzo | 2009 |
Treatment strategies targeting excess hippocampal activity benefit aged rats with cognitive impairment.
Topics: Age Factors; Aging; Animals; Anticonvulsants; CA3 Region, Hippocampal; Cognition Disorders; Disease | 2010 |
Treatment strategies targeting excess hippocampal activity benefit aged rats with cognitive impairment.
Topics: Age Factors; Aging; Animals; Anticonvulsants; CA3 Region, Hippocampal; Cognition Disorders; Disease | 2010 |
Treatment strategies targeting excess hippocampal activity benefit aged rats with cognitive impairment.
Topics: Age Factors; Aging; Animals; Anticonvulsants; CA3 Region, Hippocampal; Cognition Disorders; Disease | 2010 |
Treatment strategies targeting excess hippocampal activity benefit aged rats with cognitive impairment.
Topics: Age Factors; Aging; Animals; Anticonvulsants; CA3 Region, Hippocampal; Cognition Disorders; Disease | 2010 |
Correlation between EEG abnormalities and symptoms of autism spectrum disorder (ASD).
Topics: Adolescent; Age of Onset; Aging; Anticonvulsants; Asperger Syndrome; Autistic Disorder; Brain Mappin | 2010 |
Risk factors for late-onset seizures related to cerebral contusions in adults with a moderate traumatic brain injury.
Topics: Adult; Aged; Aging; Anticonvulsants; Brain; Brain Injuries; Carbamazepine; Electroencephalography; F | 2011 |
Animal model of autism induced by prenatal exposure to valproate: behavioral changes and liver parameters.
Topics: Aging; Alanine Transaminase; Animals; Anticonvulsants; Aspartate Aminotransferases; Autistic Disorde | 2011 |
[Epilepsy in elderly].
Topics: Aged; Aged, 80 and over; Aging; Anticonvulsants; Carbamazepine; Electroencephalography; Epilepsies, | 2011 |
Impaired social behavior in chicks exposed to sodium valproate during the last week of embryogenesis.
Topics: Aging; Animals; Anxiety, Separation; Behavior, Animal; Body Weight; Brain; Chick Embryo; Embryonic D | 2013 |
Oral/intravenous maintenance dosing of valproate following intravenous loading: a simulation.
Topics: Administration, Oral; Adult; Aging; Algorithms; Anticonvulsants; Child; Computer Simulation; Delayed | 2003 |
Valproic acid, a mood stabilizer and anticonvulsant, protects rat cerebral cortical neurons from spontaneous cell death: a role of histone deacetylase inhibition.
Topics: Aging; Animals; Anticonvulsants; Antimanic Agents; Cell Death; Cells, Cultured; Cerebral Cortex; Dos | 2003 |
Pentyl-4-yn-valproic acid reverses age-associated memory impairment in the Wistar rat.
Topics: Aging; Animals; Dose-Response Relationship, Drug; Male; Memory Disorders; Rats; Rats, Wistar; Reacti | 2004 |
The influence of old age and enzyme inducing comedication on the pharmacokinetics of valproic acid at steady-state: A case-matched evaluation based on therapeutic drug monitoring data.
Topics: Adult; Aged; Aging; Anticonvulsants; Case-Control Studies; Dose-Response Relationship, Drug; Drug In | 2006 |
Age and gender effects on olanzapine and risperidone plasma concentrations in children and adolescents.
Topics: Adolescent; Adult; Aging; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Body Weight; Chil | 2007 |
Age-related differences in susceptibility to toxic effects of valproic acid in rats.
Topics: Aging; Alanine Transaminase; Animals; Anticonvulsants; Blood Cell Count; Blood Chemical Analysis; Bo | 2008 |
Pharmacokinetics of valproic acid in the elderly.
Topics: Adult; Aged; Aging; Female; Half-Life; Humans; Kinetics; Male; Protein Binding; Valproic Acid | 1984 |
Age-dependent intestinal hydrolysis of valproate glucuronide in rat.
Topics: Aging; Animals; Glucuronates; Glucuronidase; Hydrolysis; Intestinal Mucosa; Kinetics; Male; Oxygen; | 1995 |
Age-dependent intestinal absorption of valproic acid in the rat.
Topics: Aging; Animals; Colon; Female; Glucose; Ileum; Intestinal Absorption; Intestinal Mucosa; Jejunum; Ma | 1995 |
The influence of polytherapy on the relationships between serum carbamazepine and its metabolites in epileptic children.
Topics: Aging; Anticonvulsants; Body Weight; Carbamazepine; Child; Chromatography, High Pressure Liquid; Dru | 1994 |
Increased sensitivity to the anticonvulsant effect of valproate in aging BN/BiRij rats.
Topics: Aging; Animals; Anticonvulsants; Chromatography, Gas; Electroshock; Infusions, Intravenous; Male; Ra | 1993 |
Valproic acid pharmacokinetics in children. IV. Effects of age and antiepileptic drugs on protein binding and intrinsic clearance.
Topics: Adolescent; Aging; Anticonvulsants; Child; Child, Preschool; Drug Interactions; Female; Humans; Infa | 1993 |
Valproic acid differs in its in vitro effect on glutamic acid decarboxylase activity in neonatal and adult rat brain.
Topics: Aging; Animals; Animals, Newborn; Brain; Enzyme Inhibitors; Glutamate Decarboxylase; In Vitro Techni | 1996 |
Detection of carbamazepine-induced changes in valproic acid relative clearance in man by simple pharmacokinetic screening.
Topics: Adolescent; Adult; Aging; Anticonvulsants; Body Weight; Carbamazepine; Child; Child, Preschool; Drug | 1997 |
Dose-dependent pharmacokinetics and metabolism of valproic acid in newborn lambs and adult sheep.
Topics: Aging; Animals; Animals, Newborn; Anticonvulsants; Blood Proteins; Dose-Response Relationship, Drug; | 2001 |
Pentyl-4-yn-valproic acid enhances both spatial and avoidance learning, and attenuates age-related NCAM-mediated neuroplastic decline within the rat medial temporal lobe.
Topics: Aging; Animals; Avoidance Learning; Blood Pressure; Cell Line; Heart Rate; Hippocampus; Kidney; Live | 2001 |
Influence of phenobarbital on ECoG phenomena induced by metrazol in rats during ontogenesis.
Topics: Aging; Animals; Cerebral Cortex; Clonazepam; Disease Models, Animal; Dose-Response Relationship, Dru | 1992 |
Age dependency of the susceptibility of rats to aminooxyacetic acid seizures.
Topics: Aging; Aminooxyacetic Acid; Animals; Anticonvulsants; Body Temperature; Brain; Carbamazepine; Clonaz | 1992 |
Total and free valproic acid: plasma level/dose ratio in monotherapy.
Topics: Adolescent; Adult; Aged; Aging; Child; Child, Preschool; Dose-Response Relationship, Drug; Epilepsy; | 1991 |
Inhibition of sterol but not fatty acid synthesis by valproate in developing rat brain in vivo.
Topics: Aging; Animals; Animals, Newborn; Brain; Fatty Acids; Kinetics; Mevalonic Acid; Rats; Rats, Inbred S | 1990 |
Analysis of the factors influencing anti-epileptic drug concentrations--carbamazepine.
Topics: Aging; Body Weight; Carbamazepine; Dose-Response Relationship, Drug; Drug Interactions; Female; Huma | 1990 |
Analysis of the factors influencing anti-epileptic drug concentrations--valproic acid.
Topics: Adolescent; Adult; Aging; Aspartate Aminotransferases; Body Weight; Carbamazepine; Dose-Response Rel | 1990 |
Antimetrazol action and plasma levels of valproate in developing rats.
Topics: Aging; Animals; Male; Pentylenetetrazole; Rats; Rats, Inbred Strains; Seizures; Time Factors; Valpro | 1989 |
Computerized EEG analysis of penicillin induced seizure threshold in developing rats.
Topics: Aging; Animals; Computers; Disease Models, Animal; Electroencephalography; Epilepsy; Penicillins; Ra | 1987 |